219 results
8-K
EX-99.1
RIGL
Rigel Pharmaceuticals
7 May 24
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
4:16pm
events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters … . Lung cancer is the leading cause of cancer death in the U.S, with NSCLC being the most common type accounting for 80-85% of all lung cancer diagnoses
8-K
EX-99.1
RIGL
Rigel Pharmaceuticals
5 Mar 24
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet … with lung cancer in 2024. Lung cancer is the leading cause of cancer death in the U.S, with NSCLC being the most common type accounting for 80-85% of all
8-K
EX-99.1
28m4jsnz
8 Jan 24
Rigel Pharmaceuticals Provides Business Update
8:30am
8-K
EX-99.1
597td2
7 Nov 23
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
4:16pm
8-K
EX-99.1
968o8ezbp6xcap 1j
1 Aug 23
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update
4:15pm
8-K
EX-99.1
nyjhm54m406ly h59
2 May 23
Rigel Reports First Quarter 2023 Financial Results and Provides Business Update
4:15pm
8-K
EX-99.1
fifx0
3 Nov 22
Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update
4:05pm
8-K
EX-3.1
7ux4i3b hf1vzs8uwzx
3 Nov 22
Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update
4:05pm